Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept versus laser for proliferative diabetic retinopathy
2013-004203-39Phase 2Completed
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Feb 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept in diabetic retinopathy (DR) and proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Faculty Hospital Kralovske Vinohrady. Primary endpoint: Change in ETDRS Diabetic Retinopathy Severity Score. Started Feb 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic retinopathy (DR)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2013-004203-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004203-39.